Elevated serum PAR-1 levels as an emerging biomarker of inflammation to predict the dengue infection severity.
dengue
inflammation
liver dysfunction
protease activated receptor-1
shock
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
10
09
2022
received:
11
06
2022
accepted:
13
09
2022
pubmed:
16
9
2022
medline:
11
1
2023
entrez:
15
9
2022
Statut:
ppublish
Résumé
The present study was designed to check the serum levels of protease-activated receptor (PAR-1) in patients during different phases of dengue severity. Moreover, a correlation between serum PAR-1 levels and hematological parameters, inflammatory cytokine levels, and liver functional changes was also determined. Based on the World Health Organization criteria, the study population was divided into: nonsevere dengue fever (DF; n = 30), severe dengue hemorrhagic fever (DHF; n = 19), and severe dengue shock syndrome (DSS; n = 11). The platelet count (PLT) and hematocrit (HCT) were analyzed using an automated hematology analyzer and liver function enzymes aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphate (ALP), bilirubin were checked by auto-analyzer using diagnostic kits. Moreover, the levels of inflammatory mediators C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17), and PAR-1 were determined using respective ELISA kits. The HCT levels were elevated and platelet count decreased significantly during dengue complications (DHF and DSS) compared to the DF patients, while the levels of liver functional biomarkers AST, ALT, ALP, and bilirubin remained elevated in DHF and DSS groups than in the corresponding DF group. Similarly, the inflammatory cytokine levels of CRP, TNF-α, IL-6, and IL-17 in DHF and DSS subjects were markedly increased when observed against DF subjects. Notably, the PAR-1 levels were significantly elevated in DHF and DSS groups than in the DF group and positively correlated with changes in HCT levels, inflammatory biomarkers, and liver enzymes. Our findings conclude that PAR-1 levels persistently increased with the severity of the dengue infection and are strongly associated with various clinical manifestations. Thus, PAR-1 levels can be used as a diagnostic marker for assessing dengue severity.
Substances chimiques
Interleukin-17
0
Tumor Necrosis Factor-alpha
0
Interleukin-6
0
Cytokines
0
Biomarkers
0
Bilirubin
RFM9X3LJ49
Alanine Transaminase
EC 2.6.1.2
Aspartate Aminotransferases
EC 2.6.1.1
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28152Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Hasan S, Jamdar SF, Alalowi M, Al Beaiji SM. Dengue virus. A global human threat review of literature. J Int Soc Prev Community Dent. 2016;6(1):1. doi:10.4103/2231-0762.175416
Halstead S. Recent advances in understanding dengue. F1000Research. 2019; 8(1279). doi:10.12688/f1000research.19197.1
Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue past, present and future prospects. Clin Epidemiol. 2013;5:299. doi:10.2147/CLEP.S34440
World Health Organisation. 2022. Dengue and severe dengue. Accessed August 3, 2022. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengueAccessed
Khetarpal N, Khanna I. Dengue fever: causes, complications, and vaccine strategies. J Immunol Res. 2016;2016:1-14. doi:10.1155/2016/6803098
Chuang YC, Lin YS, Liu CC, et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc. 2013;112(1):12-17. doi:10.1016/j.jfma.2012.10.013
Ong SP, Chu JJ. An update on the host factors contributing to vascular leakage during dengue virus infection. Future Virol. 2011;6(2):135-138. doi:10.2217/fvl.10.86
Lin CF, Chiu SC, Hsiao YL, et al. Expression of cytokine, chemokine, and adhesion molecules during endothelial cell activation induced by antibodies against dengue virus non-structural protein 1. J Immunol. 2005;174(1):395-403. doi:10.4049/jimmunol.174.1.395
Trung DT, Le Thi Thu Thao TT, Hien NT, et al. Liver involvement associated with dengue infection in adults in Vietnam. Am J Trop Med. 2010;83(4):774. doi:10.4269/ajtmh.2010.10-0090
Alejandria MM. Dengue haemorrhagic fever or dengue shock syndrome in children. BMJ Clin Evid. 2015;2015:0917. doi:10.5005/jp/books/11080_20
de Almeida RR, Paim B, de Oliveira SA, et al. Dengue haemorrhagic fever a state-of-the-art review focused in pulmonary involvement. Springer Sci Rev. 2017;195(4):389-395. doi:10.1007/s00408-017-0021-6
Huy NT, Van Giang T, Thuy DH, et al. Factors associated with dengue shock syndrome a systematic review and meta-analysis. PLoS neglec trop dis. 2013;7(9):e2412. doi:10.1371/journal.pntd.0002412
Lam PK, Tam DT, Diet TV, et al. Clinical characteristics of dengue shock syndrome in Vietnamese children a 10-year prospective study in a single hospital. Clin Infect Dis. 2013;57(11):1577-1586. doi:10.1093/cid/cit594
Priyadarshini D, Gadia RR, Tripathy A, et al. Clinical findings and pro-inflammatory cytokines in dengue patients in Western India a facility-based study. PLoS One. 2010;5(1):e8709. doi:10.1371/journal.pone.0008709
Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs) mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis J. 2019;17:4. doi:10.1186/s12959-019-0194-8
Liu X, Yu J, Song S, Yue X, Li Q. Protease-activated receptor-1 (PAR-1) a promising molecular target for cancer. Oncotarget. 2017;8(63):107334. doi:10.18632/oncotarget.21015
Austin KM, Covic L, Kuliopulos A. Matrix metalloproteases and PAR1 activation. Blood J Haematology Am Soc. 2013;121(3):431-439. doi:10.1182/blood-2012-09-355958
Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Investig. 1999;103(6):879-887. doi:10.1172/JCI6042
Asokananthan N, Graham PT, Fink J, et al. Activation of protease-activated receptor (PAR)−1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol. 2002;168(7):3577-3585. doi:10.4049/jimmunol.168.7.3577
Junge CE, Sugawara T, Mannaioni G, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci. 2003;100(22):13019-13024. doi:10.1073/pnas.2235594100
Pawlinski R, Tencati M, Hampton CR, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation. 2007;116(20):2298-2306. doi:10.1161/CIRCULATIONAHA.107.692764
Schoergenhofer C, Schwameis M, Gelbenegger G, et al. Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia. Thromb Haemost. 2018;118(07):1176-1184. doi:10.1055/s-0038-1655767
Saeed MA, Ng GZ, Däbritz J, et al. Protease-activated receptor 1 plays a proinflammatory role in colitis by promoting Th17-related immunity. Inflamm Bowel Dis. 2017;23(4):593-602. doi:10.1097/MIB.0000000000001045
Organji SR, Abulreesh HH, Osman GE. Circulation of dengue virus serotypes in the city of makkah, Saudi Arabia, as determined by reverse transcription polymerase chain reaction. Can J Infect Dis Med Microbiol. 2017;2017:1646701. doi:10.1155/2017/1646701
Kalayanarooj S. Clinical manifestations and management of dengue/DHF/DSS. Trop Med Health. 2011;39(4):83-87. doi:10.2149/tmh.2011-S10
Fernando S, Wijewickrama A, Gomes L, et al. Patterns and causes of liver involvement in acute dengue infection. BMC Infect Dis. 2016;16(1):1-9. doi:10.1186/s12879-016-1656-2
Vuong NL, Le Duyen HT, Lam PK, et al. C-reactive protein as a potential biomarker for disease progression in dengue a multi-country observational study. BMC Med. 2020;18(1):1-3. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-1496-1
Malavige GN, Jeewandara C, Ogg GS. Dysfunctional innate immune responses and severe dengue. Front Cell Infect Microbiol. 2020;10:600. doi:10.3389/fcimb.2020.590004
Chaloemwong J, Tantiworawit A, Rattanathammethee T, et al. Useful clinical features and hematological parameters for the diagnosis of dengue infection in patients with acute febrile illness: a retrospective study. BMC haematology. 2018;18(1):1-0. doi:10.1186/s12878-018-0116-1
Tang K, Xu W, Li M, Su Y, Wang Y, Hu R. The difference between hematocrit and plasma albumin in the course of systemic capillary leak syndrome a systematic review. Zhonghua wei Zhong Bing ji jiu yi xue. 2018;30(10):920-924. doi:10.3760/cma.j.issn.2095-4352.2018.010.002
Wisanuvej K, Boonyawat K, Savetamornkul C, et al. Comparison between blood haemoglobin concentration determined by point-of-care device and complete blood count in adult patients with dengue. PLoS Negl Trop Dis. 2021;15(8):e0009692. doi:10.1371/journal.pntd.0009692
Jayashree K, Manasa GC, Pallavi P, Manjunath GV. Evaluation of platelets as predictive parameters in dengue fever. Indian J Hematol Blood Transfus. 2011;27(3):127-130. doi:10.1007/s12288-011-0075-1
Rahat F, Khanam M, Iman K, Ghosh UK, Ghosh NK. Importance of platelet count and hematocrit in dengue fever in children. Bangla Jol of Child Health. 2020;44(2):74-77. doi:10.3329/bjch.v44i2.51129
Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 2000;181(1):2-9. doi:10.1086/315215
Guzmán MG, Kouri G, Halstead SB. Do escape mutants explain rapid increases in dengue casefatality rates within epidemics? Lancet. 2000;355(9218):1902-1903. doi:10.1016/S0140-6736(00)02303-5
Changal KH, Raina AH, Raina A, et al. Differentiating secondary from primary dengue using IgG to IgM ratio in early dengue: an observational hospital based clinico-serological study from North India. BMC Infect. 2016;16(1):1-7. doi:10.1186/s12879-016-2053-6
Khurram M, Qayyum W, Hassan SJ, Mumtaz S, Bushra HT, Umar M. Dengue hemorrhagic fever: comparison of patients with primary and secondary infections. J Infect Public Health. 2014;7(6):489-495. doi:10.1016/j.jiph.2014.05.005
Jain A, Pandey N, Garg RK, Kumar R. IL-17 level in patients with dengue virus infection & its association with severity of illness. J Clin Immunol. 2013;33(3):613-618. doi:10.1007/s10875-012-9855-0
Furuta T, Murao LA, Lan NT, et al. Association of mast cell-derived VEGF and proteases in dengue shock syndrome. PLoS Negl Trop Dis. 2012;6(2):e1505. doi:10.1371/journal.pntd.0001505
Kanwal F, Lu C, Qadri I, Sohail M, Farooqi ZU. Interleukin-6 A promising disease severity index for dengue virus infection. Asian Pac J Trop Dis. 2017;7(5):266-269. doi:10.12980/apjtd.7.2017D6-461
Rao R, Nayak S, Pandey AK, Kamath SU. Diagnostic performance of C-reactive protein level and its role as a potential biomarker of severe dengue in adults. Asian Pac J Trop Med. 2020;13(8):358. doi:10.4103/1995-7645.289440
Ayaz F, Furrukh M. Assessment of severity of dengue fever by deranged alanine aminotransferase levels. Cureus. 2020;12(9):e10539. doi:10.7759/cureus.10539
Soni A, Patel PM, Malhi NS, Avasthi GL. Spectrum of liver dysfunction in patients with dengue infection and the markers of severe disease study from a tertiary care centre in Punjab. J Liver Res Disord Ther. 2017;3(4):00063. doi:10.15406/jlrdt.2017.03.00063
Patel ND, Deepak A. Differential diagnosis of acute liver failure in India. Ann Hepatol. 2006;5(3):150-156. doi:10.1016/S1665-2681